Trial | NCT00826163  Report issue

Title

Innate Immune Responses in Chronic Obstructive Pulmonary Disease (COPD) Patients
Innate Immune Responses in Chronic Obstructive Pulmonary Disease Patients

  • Phase

    Phase 3

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    budesonide ...

  • Study Participants

    20
We hypothesize that ongoing and more severe airway inflammation in COPD may result from the impairment in activation of innate immune response
Study Started
Jan 31
2009
Primary Completion
Nov 30
2009
Study Completion
Dec 31
2009
Last Update
Sep 11
2013
Estimate

Drug Budesonide

Inhaled budesonide 400 mcg twice a day for 2 weeks

  • Other names: Rhinocort

stable COPD Active Comparator

Postbronchodilator FEV1> or = 50% predicted

Asthma Sham Comparator

Postbronchodilator FEV1 > or = 50% predicted

Criteria 

Inclusion Criteria:

clinical diagnosis of COPD or asthma
a ratio of prebronchodilator FEV1 to forced vital capacity (FVC) equal to or less than 0.70
postbronchodilator FEV1 > or = 50% predicted

Exclusion Criteria:

Exacerbation
systemic corticosteroids
DM, HIV and autoimmune disease
immunosuppressive therapy
No Results Posted